Abstract

BG24, a VRC01-class broadly neutralizing antibody (bNAb) against HIV-1 Env with relatively few somatic hypermutations (SHMs), represents a promising target for vaccine strategies to elicit CD4-binding site (CD4bs) bNAbs. To understand how SHMs correlate with BG24 neutralization of HIV-1, we report 4.1 Å and 3.4 Å single-particle cryo-EM structures of two inferred germline (iGL) BG24 precursors complexed with engineered Env-based immunogens lacking CD4bs N-glycans. Structures reveal critical Env contacts by BG24iGL and identify antibody light chain structural features that impede Env recognition. In addition, biochemical data and cryo-EM structures of BG24iGL variants bound to Envs with CD4bs glycans present provide insights into N-glycan accommodation, including structural modes of light chain adaptations in the presence of the N276gp120 glycan. Together, these findings reveal Env regions critical for germline antibody recognition and potential sites to alter in immunogen design.

VRC01-class bNAbs against the CD4 binding site of HIV-1 Env are targets of vaccine design. Here, the authors structurally characterized germline versions of the VRC01-class bNAb, BG24, bound to Env. They reveal mechanisms of germline binding, informing the design of VRC01-class targeting immunogens.

Details

Title
HIV-1 CD4-binding site germline antibody–Env structures inform vaccine design
Author
Dam, Kim-Marie A. 1   VIAFID ORCID Logo  ; Barnes, Christopher O. 2   VIAFID ORCID Logo  ; Gristick, Harry B. 1 ; Schoofs, Till 3 ; Gnanapragasam, Priyanthi N. P. 1 ; Nussenzweig, Michel C. 4   VIAFID ORCID Logo  ; Bjorkman, Pamela J. 1   VIAFID ORCID Logo 

 California Institute of Technology, Division of Biology and Biological Engineering, Pasadena, USA (GRID:grid.20861.3d) (ISNI:0000000107068890) 
 California Institute of Technology, Division of Biology and Biological Engineering, Pasadena, USA (GRID:grid.20861.3d) (ISNI:0000000107068890); Stanford University, Department of Biology, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956) 
 The Rockefeller University, Laboratory of Molecular Immunology, New York, USA (GRID:grid.134907.8) (ISNI:0000 0001 2166 1519); University of Cologne, Faculty of Medicine and University Hospital of Cologne, Laboratory of Experimental Immunology, Institute of Virology, Cologne, Germany (GRID:grid.6190.e) (ISNI:0000 0000 8580 3777); Partner Site Bonn–Cologne, German Center for Infection Research, Cologne, Germany (GRID:grid.452463.2); GlaxoSmithKline Vaccines, Rixensart, Belgium (GRID:grid.425090.a) (ISNI:0000 0004 0468 9597) 
 The Rockefeller University, Laboratory of Molecular Immunology, New York, USA (GRID:grid.134907.8) (ISNI:0000 0001 2166 1519); Howard Hughes Medical Institute, Chevy Chase, USA (GRID:grid.413575.1) (ISNI:0000 0001 2167 1581) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2725460806
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.